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Abstract
The host cellular factors that promote persistent viral infections in vivo are, in general, poorly understood. Utilizing the
hepatitis B virus (HBV) transgenic mouse model of chronic infection, we demonstrate that the nuclear receptor, hepatocyte
nuclear factor 4a (HNF4a, NR2A1), is essential for viral biosynthesis in the liver. The dependency of HBV transcription on
HNF4a links viral biosynthesis and persistence to a developmentally regulated transcription factor essential for host viability.
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Introduction
Persistent viral infections require the coexistence of pathogen
and host for extended periods of time without the host resolving
the infection or the virus killing the host. Human immunodefi-
ciency virus, herpes simplex viruses, papillomaviruses and hepatitis
B and C virus have evolved a variety of strategies to persistently
infect man [1–4]. HBV chronically infects approximately 400
million people worldwide resulting in about a million deaths per
year from liver cirrhosis and hepatocellular carcinoma [5,6]. Most
HBV infections worldwide occur in neonates at or around the time
of birth and usually result in persistent infections [6]. Although the
immunological immaturity of the neonate is presumed to
contribute to these chronic HBV infections, a precise understand-
ing of the molecular events governing HBV persistence during
development is lacking.
HBV replicates its genomic DNA by reverse transcription of a
pregenomic 3.5kb RNA which is transcribed from covalently
closed circular 3.2kb viral genomic DNA in the nucleus of infected
hepatocytes [7]. Thus transcriptional regulation plays a central
role in controlling viral replication levels [8] and represents a
potential antiviral target which has not, to date, been exploited
clinically. In cell culture, the binding of hepatocyte nuclear factor
4a (HNF4a) or retinoid X receptor a (RXRa) plus peroxisome
proliferator-activated receptor a (PPARa) to the nucleocapsid
promoter regulatory elements governs the level of synthesis of this
critical HBV pregenomic 3.5kb RNA template [9].
In this study, we demonstrate that the level of HBV
transcription and replication throughout early postnatal develop-
ment correlates with the level of liver HNF4a expression in the
HBV transgenic mouse model of chronic HBV infection. The
conditional depletion of HNF4a in the liver results in the loss of
HBV transcription and replication indicating that this nuclear
receptor is a major determinant of viral biosynthesis in vivo. These
observations indicate that viral transcription, biosynthesis and
antigen expression will increase progressively after infection at
birth, possibly contributing to persistent infection. Additionally,
the essential nature of the HNF4a transcription factor for host
viability [10–12] may limit the hosts’ ability to resolve infection
and increase the probability of viral persistence.
Results
Characterization of the conditional liver-specific HNF4a
deficient HBV transgenic mouse during early postnatal
development
Using the HBV transgenic mouse (lineage 1.3.32) model of
chronic infection [13], we previously demonstrated that PPARa
did not affect the level of viral biosynthesis under normal
physiological conditions but did mediate enhanced viral transcrip-
tion and replication in response to peroxisome proliferators [14].
To determine the role of the transcription factor HNF4a in HBV
biosynthesis, we bred HBV transgenic mice with mice carrying a
floxed HNF4a (HNF4a
fl/fl) allele [10] and albumin Cre recombi-
nase (lineage B6.Cg-Tg(Alb-cre)21Mgn/J, Jackson Laboratory)
transgene (AlbCre) [15] to generate HBVAlbCreHNF4a
fl/fl
transgenic mice. The presence of the AlbCre transgene in the
HNF4a
fl/fl mice results in the postnatal liver-specific loss of exons
4 and 5 of the HNF4a gene [10].
From the initial crosses generating HBVAlbCreHNF4a
fl/fl
transgenic mice, it was apparent that some of the pups were not
growing at the same rate as their littermates (Figure 1A and B).
Indeed, these pups were approximately 50% the weight of their
littermates between age 1 and 2 weeks (Figure 1B) and failed to
survive past 16 days. Genotyping of these mice demonstrated that
all the pups with reduced growth were Cre positive (sCre(+); small,
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within the same litter displayed growth rates closer to normal mice
(Cre(2); HNF4a
fl/fl transgenic mice lacking the AlbCre transgene)
(Figure 1B). While the liver to body weight ratio was similar (3.5+/
20.6%) for the different groups of mice throughout the first two
weeks of postnatal development, the sCre(+) mice displayed
additional features not observed in the other two groups. sCre(+)
mice sera displayed a light yellow-green coloration that became
more apparent with age. Additionally, the livers of approximately
two thirds of the 1- to 2-week-old sCre(+) mice displayed an olive-
yellow coloration rather than the dark red-brown color typically
observed in normal mice. Both of these observations are consistent
with the sCre(+) mice having an altered phenotype due to loss of
HNF4a in the liver. The observed changes in color of the sera and
livers may be due to modest increases in circulating bile acids seen
in these mice (Cre(2), Cre(+) and sCre(+) were 17+/29 mmol/l,
21+/26 mmol/l and 54+/215 mmol/l, respectively) [10] or an
accumulation of the green pigment, biliverdin, a breakdown
product of heme [16]. Similar to adult mice lacking HNF4a in
their livers, the sCre(+) pups also had reduced circulating glucose
(Figure 1C) consistent with lower HNF4a regulated gluconeogen-
esis in the liver [10,17].
Wild-type HNF4a transcript levels were measured in the liver
using reverse transcription-quantitative polymerase chain reaction
analysis specific for HNF4a exons 4 and 5 (Figure 1D) [10]. This
analysis demonstrated that while HNF4a levels increased during
early postnatal development (Figure 1D), the sCre(+) pups had
considerably lower levels of functional HNF4a transcripts
compared to the Cre(+) or Cre(2) mice throughout this time
period, consistent with their observed phenotype. Additionally,
sCre(+) mice with altered sera and liver coloration were never
observed after 16 days, suggesting that these pups either died due
to the lack of HNF4a in their hepatocytes or partially recovered as
synthesis of HNF4a returned to an adequate level during liver
development presumably due to the outgrowth of hepatocytes
where the HNF4a gene was not efficiently deleted by the Cre
recombinase.
Characterization of viral transcription in the conditional
liver-specific HNF4a deficient HBV transgenic mouse
during early postnatal development
These distinct groups of HBV transgenic mice (Cre(2), Cre(+)
and sCre(+)) exhibiting different levels of functional HNF4a
expression throughout early postnatal development permitted the
role of HNF4a in viral transcription and replication in the liver to
be determined (Figures 2 and 3). Wild-type HBV transgenic mice
(Cre(2)) displayed about a ten-fold increase in HBV 3.5kb RNA
from birth to two weeks of age (Figure 2). During the same time
period, HNF4a levels increased approximately five-fold
(Figure 1D). The Cre(+) mice which display slightly reduced levels
of HNF4a in their liver also showed reduced viral transcription
(Figure 2) while the sCre(+) mice, exhibiting a major reduction in
HNF4a levels throughout this period of development, displayed
drastically reduced levels of HBV transcription (Figure 2).
Together these data demonstrate a clear correlation between the
abundance of HBV transcripts in vivo and the level of HNF4a
during development indicating that HNF4a is essential for viral
RNA synthesis.
Characterization of viral replication in the conditional
liver-specific HNF4a deficient HBV transgenic mouse
during early postnatal development
The lower levels of viral 3.5kb pregenomic RNA associated with
diminished HNF4a abundance in the liver resulted in similarly
reduced HBV replication (Figure 3). In agreement with the
observed reduction of HNF4a (Figure 1D), the Cre(+) mice
displayed reduced levels of viral DNA synthesis throughout the
first two weeks of postnatal development and the appearance of
viral replication intermediates was delayed by at least a day
compared to the Cre(2) mice (Figure 3). Likewise, the sCre(+)
mice displayed a drastic reduction in viral replication consistent
with their much lower level of HBV transcripts (Figures 2 and 3)
and considerably lower levels of HNF4a expression (Figure 1D).
Therefore it appears that under normal physiological conditions a
single transcription factor, HNF4a, controls the early develop-
mental expression of HBV transcripts and consequently viral
replication in vivo.
Discussion
HNF4a binds the proximal regulatory element of the
nucleocapsid promoter and activates the expression of the HBV
3.5kb pregenomic RNA in cell culture [9]. Likewise, the analysis of
HBV transcription and replication throughout early postnatal
development in wild-type HBV transgenic mice and mice
conditionally deleted for HNF4a suggest that it serves the same
function in vivo. HNF4a levels increase in the liver throughout the
first two weeks of postnatal development and is associated with a
concomitant increase in both HBV RNA transcripts and DNA
replication intermediates. The liver-specific conditional disruption
of HNF4a during this period of development was associated with
two distinct phenotypes. Mice with a severe HNF4a deficiency in
the liver displayed reduced growth, altered glucose homeostasis
and a postnatal lethal phenotype. These mice synthesized limited
amounts of HBV transcripts and replication intermediates. Mice
that were close to displaying a normal phenotype with respect to
growth and glucose homeostasis exhibited a modest decrease in
liver HNF4a levels that was associated with a similar decrease in
both viral RNA and DNA synthesis. These observations indicate
that HBV transcription and hence viral replication is dependent
on HNF4a. Although it is likely that HNF4a directly activates
HBV transcription [9], it is also possible that HNF4a might
control the expression of additional factors necessary for efficient
viral transcription and replication in vivo. Additionally, the
hepatotoxicity resulting from extensive HNF4a loss may contrib-
ute to the observed reduction in HBV transcription and
replication by unknown mechanisms.
These studies highlight an interesting relationship between
HBV biosynthesis and liver-specific gene expression. We show
HNF4a is essential in vivo to sustain active viral transcription and
subsequent replication. Similarly, HNF4a is required for HBV
host viability. The absence of HNF4a or its conditional loss from
the liver is fatal in the mouse [10–12]. Haploinsufficiency of
Figure 1. Effects of liver-specific conditional deletion of HNF4a on postnatal growth, serum glucose and HNF4a transcript levels. (A)
HBVAlbCre(+)HNF4a
fl/fl pup with the small phenotype, sCre(+), and a control HBVAlbCre(2)HNF4a
fl/fl littermate, Cre(2), at 5.5 days of age. (B) Effect
of postnatal age on body weight. (C) Effect of postnatal age on serum glucose levels. (D) Effect of postnatal age on wild-type HNF4a RNA levels in the
liver measured by reverse transcription-quantitative polymerase chain reaction. Cre(2), control HBVAlbCre(2)HNF4a
fl/fl mice; Cre(+),
HBVAlbCre(+)HNF4a
fl/fl mice with approximately wild-type phenotype; sCre(+), HBVAlbCre(+)HNF4a
fl/fl mice with the small phenotype.
doi:10.1371/journal.pone.0005489.g001
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young type 1 (MODY1) [18,19]. Humans with a complete loss of
HNF4a have not been reported presumably because, as in mice, it
results in early embryonic lethality. Curiously, the adaptation of
HBV to utilize HNF4a, an essential host gene product, guarantees
constitutive replication of its genome as long as the host is viable.
This adaptation may contribute to HBV persistence and offer
the virus a significant selective advantage over other pathogens
that utilize cellular components that are less important to host
survival.
The vast majority of HBV infections acquired in adolescence
and early adulthood are successfully cleared by the host. In
contrast, most HBV infections that occur at birth result in chronic
infection [20] despite the ability of neonates to mount an antiviral
immune response if vaccinated [21]. The parallel increase in
HNF4a expression and HBV biosynthesis levels observed during
postnatal development in our study suggest that neonatal HBV
infection is associated with a slow developmentally regulated
increase in viral transcription, replication and antigen expression
which may contribute to life long chronic infection [20,22].
Figure 2. HBV RNA transcripts in the livers of HBV transgenic mice throughout early postnatal development. (A) RNA (Northern) filter
hybridization analysis of representative examples of HBV transcripts at various stages of postnatal liver development. The glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) transcript was used as an internal control for the quantification of the HBV 3.5 and 2.1kb RNAs. The probes used
were HBVayw genomic DNA plus GAPDH cDNA[26]. Cre(2), control HBVAlbCre(2)HNF4a
fl/fl mice; Cre(+), HBVAlbCre(+)HNF4a
fl/fl mice with
approximately wild-type phenotype; sCre(+), HBVAlbCre(+)HNF4a
fl/fl mice with the small phenotype. (B) Quantitative analysis of the HBV 3.5kb
transcript in HBVAlbCreHNF4a
fl/fl transgenic mice. Trend lines were calculated using linear regression analysis.
doi:10.1371/journal.pone.0005489.g002
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gene products at this stage of development, such as the fibrate class
of hyperlipidemic drugs [14], might modulate the immune
response of the host to viral antigens and help immunological
resolution of these neonatal infections.
The observation that HBV is critically dependent on at least one
cellular factor offers a unique target for antiviral therapy. However
this opportunity comes with the difficult challenge of inhibiting
HNF4a without completely eliminating its essential cellular
functions. Nevertheless, mice exhibiting only a modest decrease
Figure 3. HBV DNA replication intermediates in the livers of HBV transgenic mice throughout early postnatal development. (A) DNA
(Southern) filter hybridization analysis of representative examples of HBV replication intermediates (RI) at various stages of postnatal liver
development. The HBV transgene (Tg) was used as an internal control for the quantification of the HBV replication intermediates. The probe used was
HBVayw genomic DNA[26]. Cre(2), control HBVAlbCre(2)HNF4a
fl/fl mice; Cre(+), HBVAlbCre(+)HNF4a
fl/fl mice with approximately wild-type
phenotype; sCre(+), HBVAlbCre(+)HNF4a
fl/fl mice with the small phenotype; Tg , HBV transgene; RC, HBV relaxed circular replication intermediates; SS,
HBV single stranded replication intermediates. (B) Quantitative analysis of the HBV replication intermediates in HBVAlbCreHNF4a
fl/fl transgenic mice.
Trend lines were calculated using linear regression analysis.
doi:10.1371/journal.pone.0005489.g003
In Vivo Regulation of HBV
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5489in HNF4a levels displayed a detectable reduction in HBV RNA
and DNA levels while maintaining virtually normal growth and
glucose homeostasis (Figure 1). Furthermore, newborn pups
express enough HNF4a for viability but not enough to support
HBV replication. If HNF4a activity levels can be attenuated
clinically to limit HBV biosynthesis while minimally affecting liver
physiology, this might offer a novel therapeutic strategy to
complement currently available antiviral drugs targeting the
HBV reverse transcriptase [20]. Metformin, a drug widely used
to treat type 2 diabetes, reduces peroxisome proliferator-activated
receptor c coactivator 1a expression and gluconeogenesis in the
liver suggesting pharmacological intervention may be successful in




All animal experiments were performed according to institu-
tional guidelines with Institutional Biosafety and Animal Care
Committee approval.
Transgenic mice
We bred HBV transgenic mice (lineage 1.3.32) [13] with mice
carrying a floxed HNF4a (HNF4a
fl/fl) allele [10] and albumin Cre
(lineage B6.Cg-Tg(Alb-cre)21Mgn/J, Jackson Laboratory) trans-
gene (AlbCre) [15] to generate HBVAlbCreHNF4a
fl/fl transgenic
mice. All the mouse strains had been crossed for twelve
generations onto the SV129 genetic background [25] prior to
generating the HBVAlbCreHNF4a
fl/fl transgenic mice. Mice were
screened for the HBV transgene, the AlbCre transgene and the
floxed HNF4a allele by polymerase chain reaction (PCR) analysis
of tail DNA [26]. The HBV transgene was identified by PCR
analysis using the oligonucleotides, 59-TCGATACCT-
GAACCTTTACCCCGTTGCCCG-39 (oligo XpHNF4-1, HBV
coordinates 1133 to 1159) and 59-TCGAATTGCTGAGAGTC-
CAAGAGTCCTCTT-39 (oligo CpHNF4-2, HBV coordinates
1683 to 1658), and 1 ml of tail DNA. A PCR product of 551 base
pairs indicated the presence of the HBV transgene. The AlbCre
transgene was identified by PCR analysis using the oligonucleo-
tides, 59-CCAGCTAAACATGCTTCATCGTCG-39 (oligo
CRE-1) and 59-ATTCTCCCACCGTCAGTACGTGAG-39
(oligo CRE-2), and 1 ml of tail DNA. A PCR product of 300
base pairs indicated the presence of the Cre transgene. The
HNF4a wild-type and floxed alleles were identified by PCR
analysis using the oligonucleotides, 59-AGAATGACCCTGAAG-
CACCAGG-39 (oligo prH4GTLP1-F1) and 59-GCCA-
GAGGTCTGTGAAACAAGG-39 (oligo prH4GT-LP1-R1), and
1 ml of tail DNA. PCR products of 180 and 241 base pairs
indicated the presence of the wild-type and floxed HNF4a alleles,
respectively [10]. Serum glucose levels were measured using a
SureStep blood glucose meter (Lifescan).
HBV DNA and RNA analysis
Total DNA and RNA were isolated from liver of HBV
transgenic mice as described [27,28]. DNA (Southern) filter
hybridization analyses were performed using 20 mgo fHindIII
digested DNA [27]. Filters were probed with
32P-labeled HBVayw
genomic DNA [29] to detect HBV sequences. RNA (Northern)
filter hybridization analyses were performed using 10 mg of total
cellular RNA as described [27]. Filters were probed with
32P-
labeled HBVayw genomic DNA to detect HBV sequences and
mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
cDNA to detect the GAPDH transcript used as an internal
control [30]. Filter hybridization analyses were quantitated by
phosphorimaging using a Packard Cyclone Storage Phosphor
System.
Reverse transcription-quantitative polymerase chain reaction
was used to measure the level of HNF4a transcripts in mouse liver
RNA. After DNase I treatment, 1 mg of RNA was used for cDNA
synthesis using the TaqMan reverse transcription reagents
(Applied Biosystems, Foster City, CA), followed by real-time
PCR quantification using SYBR Green and an Applied Biosys-
tems 7300 real-time thermocycler (Applied Biosystems). Thermal
cycling consisted of an initial denaturation step for 10 min at 95uC
followed by 40 cycles of denaturation (15 sec at 95uC) and
annealing/extension (1 min at 60uC). The relative HNF4a RNA
expression levels were estimated using the DDCt method with
normalization to mouse GAPDH RNA. The PCR primers used
were 59-TCAACGCGCTCCTGC-39 (HNF4a exon 4 sense
primer), 59-AATCTTCTTTGCCCGAATGT-39 (HNF4a exon
5 antisense primer), 59-TCTGGAAAGCTGTGGCGTG-39
(mouse GAPDH sense primer) and 59-CCAGTGAGCTT-
CCCGTTCAG-39 (mouse GAPDH antisense primer).
Acknowledgments
We thank Luca G. Guidotti and Francis V. Chisari (The Scripps Research
Institute, La Jolla, CA) for providing the HBV transgenic mice. We thank
Linda Kenney, Bellur Prabhakar, David Ucker and William Walden for
many helpful discussions and critical reading of the manuscript. We are
grateful to Iain McLachlan for the photographic imaging of the HBV
transgenic mice.
Author Contributions
Conceived and designed the experiments: AM. Performed the experiments:
LL CEO BS AM. Analyzed the data: LL CEO BS AM. Contributed
reagents/materials/analysis tools: FJG. Wrote the paper: SLU AM.
References
1. Geeraert L, Kraus G, Pomerantz RJ (2008) Hide-and-seek: the challenge of viral
persistence in HIV-1 Infection. Annu Rev Med 59: 487–501.
2. Knipe DM, Cliffe A (2008) Chromatin control of herpes simplex virus lytic and
latent infection. Nat Rev Micro 6: 211–221.
3. Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol
109: S15–S21.
4. Gale M, Foy EM (2005) Evasion of intracellular host defence by hepatitis C
virus. Nature 436: 939–945.
5. Lok AS, Heathcote EJ, Hoofnagle JH (2001) Management of hepatitis B: 2000 -
Summary of a workshop. Gastroenterology 120: 1828–1853.
6. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment,
and current and emerging prevention and control measures. J Viral Hepat 11:
97–107.
7. Will H, Reiser W, Weimer T, Pfaff E, Buscher M, et al. (1987) Replication
strategy of human hepatitis B virus. J Virol 61: 904–911.
8. Tang H, Banks KE, Anderson AL, McLachlan A (2001) Hepatitis B virus
transcription and replication. Drug News Perspect 14: 325–334.
9. Tang H, McLachlan A (2001) Transcriptional regulation of hepatitis B virus by
nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl
Acad Sci USA 98: 1841–1846.
10. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Hepatocyte
nuclear factor 4a (nuclear receptor 2A1) is essential for maintenance of hepatic
gene expression and lipid homeostasis. Mol Cell Biol 21: 1393–1403.
11. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, et al. (2003)
Hepatocyte nuclear factor 4a controls the development of a hepatic epithelium
and liver morphogenesis. Nature Genet 34: 292–296.
12. Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, et al. (1994)
Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell
death in embryonic ectoderm and impaired gastrulation of mouse embryos.
Genes Dev 8: 2466–2477.
In Vivo Regulation of HBV
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e548913. Guidotti LG, Matzke B, Schaller H, Chisari FV (1995) High-level hepatitis B
virus replication in transgenic mice. J Virol 69: 6158–6169.
14. Guidotti LG, Eggers CM, Raney AK, Chi SY, Peters JM, et al. (1999) In vivo
regulation of hepatitis B virus replication by peroxisome proliferators. J Virol 73:
10377–10386.
15. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, et al. (1999) Dual roles
for glucokinase in glucose homeostasis as determined by liver and pancreatic
beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:
305–315.
16. Fenech FF, Bannister WH, Grech JL (1967) Hepatitis with biliverdinaemia in
association with indomethacin therapy. Br Med J 3: 155–156.
17. Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan ML, et al. (2003) Regulation of
hepatic fasting response by PPARc coactivator-1a (PGC-1): Requirement for
hepatocyte nuclear factor 4a in gluconeogenesis. Proc Natl Acad Sci USA 100:
4012–4017.
18. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, et al. (1996) Mutations in
the hepatocyte nuclear factor-4a gene in maturity- onset diabetes of the young
(MODY1). Nature 384: 458–460.
19. Shih DQ, Dansky HM, Fleisher M, Assmann G, Fajans SS, et al. (2000)
Genotype/phenotype relationships in HNF-4a/MODY1 - Haploinsufficiency is
associated with reduced apolipoprotein(AII), apolipoprotein(CIII), lipoprotein(a),
and triglyceride levels. Diabetes 49: 832–837.
20. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359: 1486–1500.
21. Del Canho R, Grosheide PM, Voogd-Schotanus M, Huisman WM, Heijtink RA,
et al. (1994) Immunogenicity of two different dosages (10 and 5 mg) of
recombinant DNA hepatitis B vaccine in healthy neonates. Vaccine 12:
1323–1326.
22. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, et al. (1990) Is a function of
the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc
Natl Acad Sci USA 87: 6599–6603.
23. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase
LKB1 mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science (New York), N Y 310: 1642–1646.
24. Shlomai A, Paran N, Shaul Y (2006) PGC-1a controls hepatitis B virus through
nutritional signals. Proc Natl Acad Sci USA 103: 16003–16008.
25. Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, et al. (1995) Targeted
disruption of the a isoform of the peroxisome proliferator-activated receptor
gene in mice results in abolishment of the pleiotropic effects of peroxisome
proliferators. Mol Cell Biol 15: 3012–3022.
26. Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLachlan A (2005) Alpha/
beta interferon differentially modulates the clearance of cytoplasmic encapsi-
dated replication intermediates and nuclear covalently closed circular hepatitis B
virus (HBV) DNA from the livers of hepatocyte nuclear factor 1a-null HBV
transgenic mice. J Virol 79: 11045–11052.
27. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory
manual. New York: Cold Spring Harbor Laboratory Press.
28. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:
156–159.
29. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P (1979) Nucleotide
sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature
281: 646–650.
30. Sabath DE, Broome HE, Prystowsky MB (1990) Glyceraldehyde-3-phosphate
dehydrogenase mRNA is a major interleukin 2- induced transcript in a cloned
T-helper lymphocyte. Gene 91: 185–191.
In Vivo Regulation of HBV
PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5489